Project/Area Number |
15K10161
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | University of Toyama (2017) Nagoya University (2015-2016) |
Principal Investigator |
FUJII TSUTOMU 富山大学, 大学院医学薬学研究部(医学), 教授 (60566967)
|
Co-Investigator(Kenkyū-buntansha) |
神田 光郎 名古屋大学, 医学部附属病院, 助教 (00644668)
小寺 泰弘 名古屋大学, 医学系研究科, 教授 (10345879)
山田 豪 名古屋大学, 医学部附属病院, その他 (30467287)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 肝癌 / 肝障害抑制モデル / EGFR阻害剤 / ラット / 肝星細胞 / DEN / Erlotinib / 肝硬変モデル |
Outline of Final Research Achievements |
In recent years, researchers reported the effect of inhibiting cirrhosis by epidermal growth factor receptor (EGFR) inhibitors in animal models (Hepatology 2014). In this research, we clarified the mechanism of this phenomenon concretely and aimed at the development of a treatment method from a new viewpoint that suppresses cirrhotic changes of the liver in humans. Examination of protein expression in rat cirrhosis suppression model, examination of marker expression of Hepatic Stellate Cell, and isolation culture and examination of gene / protein expression in human HCC specimens, were performed.
|